Press releases
Volastra Therapeutics Announces the Appointment of Co-Founder Samuel Bakhoum, M.D., Ph.D., as Chief Scientific Officer
Volastra Therapeutics, a clinical-stage pharmaceutical company developing innovative cancer therapies targeting chromosomal instability, today announced the appointment of Volastra Co-Founder, Samuel Bakhoum, M.D., Ph.D., as its Chief Scientific Officer (CSO).
Volastra Therapeutics Granted FDA Fast Track Designation for Novel KIF18A Inhibitor in Ovarian Cancer
Volastra Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, the company’s internally discovered KIF18A inhibitor.
Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib
Volastra Therapeutics, a clinical-stage biotechnology company, today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC).
Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer
Microsoft, Function Oncology and Tailor Bio collaborations will support the evolution of predictive biomarkers across a diversity of tumors
Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors
Volastra Therapeutics, a clinical-stage cancer biotechnology company, has appointed David Nicholson, Ph.D., as an independent member of its Board of Directors.
Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
Volastra Therapeutics, a discovery and clinical-stage cancer biotechnology company, today announced the dosing of the first patient in a Phase I/II clinical trial evaluating VLS-1488.
Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today […]
Volastra Therapeutics Announces the Appointment of Co-Founder Samuel Bakhoum, M.D., Ph.D., as Chief Scientific Officer
Volastra Therapeutics, a clinical-stage pharmaceutical company developing innovative cancer therapies targeting chromosomal instability, today announced the appointment of Volastra Co-Founder, Samuel Bakhoum, M.D., Ph.D., as its Chief Scientific Officer (CSO).
Volastra Therapeutics Granted FDA Fast Track Designation for Novel KIF18A Inhibitor in Ovarian Cancer
Volastra Therapeutics, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VLS-1488, the company’s internally discovered KIF18A inhibitor.
Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib
Volastra Therapeutics, a clinical-stage biotechnology company, today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC).
Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer
Microsoft, Function Oncology and Tailor Bio collaborations will support the evolution of predictive biomarkers across a diversity of tumors
Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors
Volastra Therapeutics, a clinical-stage cancer biotechnology company, has appointed David Nicholson, Ph.D., as an independent member of its Board of Directors.
Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
Volastra Therapeutics, a discovery and clinical-stage cancer biotechnology company, today announced the dosing of the first patient in a Phase I/II clinical trial evaluating VLS-1488.